On February 17, 2026, One Fin Capital Administration absolutely exited its place in GRAIL (NASDAQ:GRAL), promoting roughly 380,000 shares price $22.47 million.
In accordance with a Securities and Alternate Fee (SEC) submitting dated February 17, 2026, One Fin Capital Administration reported the whole sale of its 380,000-share stake in GRAIL. The fund reported a quarter-end place worth lower of $22.47 million on account of the sale.
-
The liquidation means GRAIL now represents 0% of the fund’s 13F AUM, down from 7.4% within the prior interval.
-
Prime holdings after the submitting:
-
NYSE:COF: $31.88 million (12.1% of AUM)
-
NASDAQ:NXT: $26.13 million (9.9% of AUM)
-
NYSE:RKT: $25.75 million (9.8% of AUM)
-
NASDAQ:DRVN: $24.30 million (9.2% of AUM)
-
NYSE:NSC: $23.10 million (8.8% of AUM)
-
-
As of Friday, shares of GRAIL have been priced at $46.84, up 68% this previous 12 months, effectively outperforming the S&P 500, which is as a substitute up about 15% in the identical interval.
|
Metric |
Worth |
|---|---|
|
Market Capitalization |
$1.9 billion |
|
Value (as of Friday) |
$46.84 |
|
Income (TTM) |
$147.2 million |
|
Internet Earnings (TTM) |
($408.35 million) |
-
GRAIL develops early most cancers detection applied sciences, together with the Galleri screening take a look at and diagnostic aids for most cancers, with further work on minimal residual illness and post-diagnostic instruments.
-
The agency generates income primarily by means of gross sales of proprietary diagnostic assessments and associated providers, concentrating on the healthcare diagnostics market.
-
Its most important prospects embrace healthcare suppliers, clinicians, and asymptomatic people over 50 searching for proactive most cancers screening options.
GRAIL is a biotechnology firm specializing in blood-based multi-cancer early detection and diagnostic options. Leveraging superior genomics and information science, it goals to remodel most cancers screening and prognosis at scale. Its proprietary know-how and deal with early detection place it as a pacesetter within the quickly evolving medical diagnostics panorama.
This transfer issues as a result of it reveals self-discipline proper earlier than a high-conviction development story handled a shocking blow. GRAIL had been, and in some methods nonetheless is, a standout performer, using optimism round its early most cancers detection platform and robust business traction, together with greater than 185,000 Galleri assessments offered and income development into the $147 million vary final 12 months. However beneath that momentum, the enterprise nonetheless carries heavy losses and execution threat tied to regulatory approval and adoption curves.
That pressure got here into focus quick. A pointy, roughly 50% single-day drop following earnings highlights simply how fragile sentiment will be when expectations run forward of fundamentals.
One Fin’s broader portfolio, in the meantime, leans towards a mixture of financials, industrials, and consumer-facing names, suggesting a deal with corporations with extra predictable money flows and clearer near-term earnings visibility. Finally, for long-term buyers, this looks like a very good reminder that self-discipline issues, and balancing threat after staggering upside will help you sit out some steep declines.